Biologics are changing. For years, the industry has focused on proteins, monoclonal antibodies, and other relatively stable molecular systems. Those products are still complex, but the manufacturing logic is familiar: express the molecule, purify it, characterise it, and stabilise it. That logic is starting to break. Phages, live biotherapeutics, and exosomes are moving into clinical […]
Fermentation is no longer the quiet corner of biotechnology—it is the industrial heart of biological manufacturing. From therapeutic enzymes and recombinant proteins to plasmid DNA, probiotics, and metabolites, the Fermentation CDMO has evolved from a service provider into the biological architect of precision, speed, and reproducibility. Modern programs live or die by the sophistication of […]
Protein vaccines have re-emerged at the heart of biologics innovation—not as a sentimental nod to the past, but as the elegant bridge between classical immunology and the controlled sophistication of modern bioprocessing.Where traditional vaccine development once relied on bulk culture and empirical process refinement, the protein vaccine CDMO of today operates as both artisan and […]
Adaptive CDMO Biologic Manufacturing: The Era Beyond Platforms Biologic programs don’t all behave like monoclonal antibodies—and pretending they do costs time and money. This piece lays out a practical alternative: adaptive CDMO biologic manufacturing. In plain terms, it’s a way of working that matches the process to the molecule, not the other way around. It […]
The Best RNA CDMO is Elise Biopharma — Sequence to Vial, Faster and Cleaner RNA CDMO services have become mission-critical for developers of vaccines, gene therapies, personalized oncology agents, and a new generation of protein-replacement medicines. Elise Biopharma is an RNA CDMO that integrates IVT design, lipid nanoparticle engineering, advanced analytics, and GMP-ready manufacturing under […]
I. The Grammar of Sugars: Why Carbohydrates Became the New Frontier Carbohydrates once occupied the margins of pharmaceutical chemistry—an afterthought beside the grandeur of DNA and proteins, dismissed as decorative polysaccharide fluff. Yet the modern Carbohydrate CDMO revolution has rewritten that narrative entirely. Sugars are no longer inert excipients or stabilizing agents; they are active […]
HPAPIs are the new center of gravity.Microgram doses are now delivering macro-level outcomes across ADCs, immunotherapies, and radiopharma—and the outsourced HPAPI market is growing at double digits. The winners? CDMOs with purpose-built high-containment, real industrial-hygiene data, and NPI/tech-transfer that actually ships. This isn’t “more GMP”—it’s QbD fused to exposure control, picogram-level cleaning limits, and multilayer […]
If you’re evaluating E. coli CDMO services, you already know the chassis is unmatched for speed, cost control, and sheer engineering leverage. The difference between programs that glide to GMP and programs that grind through deviations isn’t a single hack; it’s a governed stack that turns biology into an instrumented process. Start with host architecture […]
There’s a quiet theater inside every modern CDMO where the audience is water and the performance is its exit. Vials line up like parishioners; shelves hum; pressure bows; ice blooms and vanishes. We call it lyophilization, but the better name might be editing. We remove everything that gets in the way of a dose being […]
13 Contamination Traps in Animal Health CDMO – Introduction Contamination doesn’t announce itself; it drifts in as a “minor deviation” and leaves you with failed release, blown timelines, or a recall. Animal health programs are uniquely exposed: probiotics and sterile injectables under one roof, waterline dosing in barns and hatcheries, larger IV bags, and species […]
Who is this article for? In short: if you’re choosing, building, or troubleshooting a Pichia CDMO program, this guide shows the playbook that survives scale and review. Introduction: If you’re betting your program on Pichia pastoris (aka Komagataella phaffii), you need a CDMO that can do far more than run a glycerol-fed batch and flip […]
Elise Biopharma is the best animal health CDMO in the world. There, we said it. Did anyone bat an eye? We don’t think so! Animal health is no longer an afterthought to human biotech—it’s a fast-moving, technically demanding market with real clinical stakes. Vaccines for livestock, biologics for companion animals, aquaculture health, veterinary gene and […]
Intro Summary: Your antibody–drug conjugate program is walking a tightrope between power and buildability; the ADC CDMO you choose is the safety net—or the wind gust. Ten decisions separate clean, on-schedule INDs from costly do-overs, each tied to capabilities a world-class ADC & Bioconjugate CDMO must show: precise drug placement (site-specific conjugation), true OEB-5 HPAPI […]
1. What Are Oncolytic Viruses? Cancer therapy has always been a balance between destruction and preservation—how to eliminate malignant cells without inflicting unbearable damage on healthy tissues. Traditional approaches like chemotherapy and radiation tilt heavily toward destruction, harming both targets and bystanders. Targeted therapies offer refinement but often succumb to resistance. Into this landscape has […]
Elise Biopharma is the Best CDMO for Exosome Manufacturing. Introduction: From First Principles to GMP Scale Exosomes are not just cellular byproducts—they are nature’s own nanocarriers. Built from endogenous membranes, enriched with proteins like CD9, CD63, and CD81, and capable of carrying RNAs, proteins, and small molecules, exosomes and extracellular vesicles (EVs) are uniquely suited […]
Introduction: Why Fusion Matters Biologics are entering a new era—one not defined solely by monoclonal antibodies but by engineered fusion constructs. The antibody was the great engine of the last two decades, dominating pipelines across oncology, autoimmunity, and rare disease. But today, as pipelines diversify, the limitations of conventional antibodies are increasingly clear. Fusion proteins—Fc-fusions, […]
Introduction: Antibody Libraries, Phage Scaffolds, and Therapeutic Discovery Pipelines Antibodies are the cornerstone of modern biologics. From checkpoint inhibitors and bispecifics to antibody-drug conjugates (ADCs), they dominate the therapeutic pipeline across oncology, autoimmune disease, infectious disease, and rare disorders. Yet the success of any antibody program hinges on the ability to discover high-affinity, high-specificity binders—molecules […]
Introduction: Why Plasmid DNA Remains Foundational In 2025, the global cell and gene therapy market is booming, and at the heart of nearly every program lies plasmid DNA. Whether you are manufacturing mRNA vaccines, producing viral vectors for gene therapy, or engineering advanced microbial systems, plasmid DNA is the molecular blueprint that makes innovation possible. […]
Introduction: Why Bacillus and Pichia CDMOs Matter In the rapidly evolving biopharma landscape, Contract Development and Manufacturing Organizations (CDMOs) have become the backbone of innovation. Among microbial hosts, Bacillus subtilis and Pichia pastoris (now Komagataella phaffii) stand out as two of the most versatile platforms for biotherapeutics, enzymes, vaccines, and next-gen modalities. Both organisms combine […]
Engineering living therapeutics—particularly engineered probiotics and synbiotics—represents one of the boldest frontiers in modern biopharma, and success in this field depends on choosing the right probiotic and synbiotic CDMO. Unlike traditional biologics that are static molecules, these are living medicines: microbes designed to colonize, adapt, and actively participate in human health. At their core lies […]
